Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435

[1]  H. Lithell,et al.  ST-1435: development of an implant. , 1984 .

[2]  I. Sivin,et al.  Release rates of levonorgestrel from Silastic capsules, homogeneous rods and covered rods in humans. , 1983, Contraception.

[3]  H. Croxatto,et al.  Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. , 1983, Contraception.

[4]  H. Lithell,et al.  Effects of progestins on lipoprotein patterns. , 1983 .

[5]  G. Hammond,et al.  Distribution and percentages of non-protein bound contraceptive steroids in human serum. , 1982, Journal of steroid biochemistry.

[6]  T. Luukkainen,et al.  Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST-1435. , 1982, Contraception.

[7]  H. Lithell,et al.  Serum Lipoprotein and Apolipoprotein Changes During Treatment with a Contraceptive Vaginal Ring Containing Levonorgestrel and Estradiol , 1982, Acta obstetricia et gynecologica Scandinavica.

[8]  L. Havekes,et al.  High density lipoprotein cholesterol and apolipoprotein A-I levels in 32-33-year-old women on steroid contraceptives-differences between two frequently used low-estrogen pills. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[9]  H. Lithell,et al.  Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. I. Carbohydrate metabolism and liver function. , 1981, Contraception.

[10]  H. Lithell,et al.  Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II. Serum lipoproteins and apolipoproteins. , 1981, Contraception.

[11]  S. Shapiro,et al.  Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. , 1981, The New England journal of medicine.

[12]  L. Wallentin,et al.  Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. , 1981, Fertility and sterility.

[13]  H. Lithell,et al.  Reduction of high density lipoprotein cholesterol and apoliproprotein A-I concentrations by a lipid-lowering diet. , 1980, Atherosclerosis.

[14]  R. Krauss,et al.  Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. , 1978, The New England journal of medicine.

[15]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[16]  W. Spellacy,et al.  The effects of norgestrel on carbohydrate and lipid metabolism over one year. , 1976, American Journal of Obstetrics and Gynecology.

[17]  A Kagan,et al.  Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. , 1976, The New England journal of medicine.